---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-013435"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:07:45.088204+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Avalo acquires Phase 2-ready anti-IL-1β mAb via merger with AlmataBio, raises $115.6M PIPE

## Summary
- Acquired AlmataBio for ~$15M in stock (171,605 common shares + 2,412 Series C Preferred), plus up to $27.5M in milestones.
- Concurrent PIPE of $115.6M upfront (up to $185M total) led by Commodore Capital and TCGX; net proceeds ~$105M.
- Lead asset AVTX-009 (anti-IL-1β mAb, ex-Eli Lilly) is Phase 2-ready for hidradenitis suppurativa; topline data expected 2026.
- Cash runway extended into 2027; board expanded to 9 with appointments of Jonathan Goldman, Aaron Kantoff, Samantha Truex.

## SEC filing metadata
- accession: 0001628280-24-013435
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/0001628280-24-013435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/avtx-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-013435
- JSON: https://secwatch.observer/filing/0001628280-24-013435.json
- Plain text: https://secwatch.observer/filing/0001628280-24-013435.txt

## Key facts
- Executive change
  Aaron Kantoff was appointed as Director at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/0001628280-24-013435-index.htm
- Executive change
  Jonathan Goldman was appointed as Director at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Jonathan Goldman was appointed to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/0001628280-24-013435-index.htm
- Executive change
  Samantha Truex was appointed as Director at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/0001628280-24-013435-index.htm
- M&A Transactions
  Avalo Therapeutics, Inc. completed an acquisition involving AlmataBio, Inc. for 171,605 shares of Common Stock and 2,412 shares of Series C Preferred Stock valued at approximately $15 million (closed 2024-03-27).
  - Action: acquisition
  - Counterparty: AlmataBio, Inc.
  - Consideration: 171,605 shares of Common Stock and 2,412 shares of Series C Preferred Stock valued at approximately $15 million
  - Closing: 2024-03-27
  source text: or employee of the Company or the Subsidiary following completion of the Merger. As consideration for the Merger, the Company issued to the Almata stockholders an aggregate of 171,605 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and an aggregate of 2,412 shares of Series C Preferred Stock (as defined and described in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024013435/0001628280-24-013435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.